|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The FGFR3<sup>S249C</sup> mutation may therefore be used as a predictor of chemosensitivity in patients with BCa.
|
31316618 |
2019 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of FGFR3 and PIK3CA mutated DNA in urine and plasma are indicative of later progression and metastasis in bladder cancer.
|
28069289 |
2017 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
CTD_human |
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation.
|
24121792 |
2013 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
|
16885334 |
2006 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this clinical follow-up study was to investigate the role of FGFR3 mutations in bladder cancer development in a longitudinal study.
|
16278391 |
2005 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion we retain that activated RAS and FGFR3 do not appear to be drivers in bladder cancer but the mutually exclusive relationship between RAS and FGFR3 mutations indicates a possible clonal advantage of modified signaling via a common pathway.
|
22820081 |
2012 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
|
21264819 |
2011 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders.
|
12461689 |
2002 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
|
28049011 |
2017 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The phenotypic consequences of constitutive activation of FGFR3 in bladder cancer have not been elucidated and further studies are required to confirm the consequences of inhibiting receptor activity in urothelial cells.
|
17384684 |
2007 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In summary, alternative splicing of FGFR3 IIIb in NHU cells represents a normal mechanism to generate a transcript that regulates proliferation and in bladder cancer, the ratio of FGFR3 isoforms is significantly altered.
|
16288035 |
2005 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We further demonstrate that activating mutations in FGFR3 associated with both multiple myeloma and bladder cancer can modulate expression of genes that regulate NFκB signaling, and promote both NFκB transcriptional activity and cell adhesion in a manner dependent on TAK1 expression in both cancer cell types.
|
24466111 |
2014 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Two bladder cancer cell lines that harbor FGFR3 fusion proteins exhibited enhanced susceptibility to pharmacologic inhibition in vitro and in vivo.
|
23558953 |
2013 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine.
|
16278395 |
2005 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
FGFR3-TACC3 fusion transcripts were identified by RNA-FISH and RT-PCR in mouse xenograft FFPE tissues using the human BC cell lines RT112 and RT4.
|
27930669 |
2016 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The greater sensitivity of FGFR3 mutation detection over cytology in identifying the presence of low-grade, superficial bladder tumors represents a potential new tool to complement standard cytology in screening patients for bladder tumors and recurrent disease.
|
12910517 |
2003 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
In addition, several FGFRs are mutated in human cancers (including FGFR2 in gastric cancer and FGFR3 in bladder cancer).
|
17697126 |
2007 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
FGFR3 mutations occur in 70% of nonmuscle invasive bladder tumors.
|
21683397 |
2011 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In bladder carcinoma, we recently identified FGFR3 mutations in 41% of tumours, making this the most frequently mutated putative oncogene identified in bladder cancer to date.
|
11466624 |
2001 |
|
Bladder Neoplasm
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Bladder cancer cell lines were exposed to normoxic or hypoxic conditions and examined for the expression of FGFR3 by quantitative PCR (qPCR) and western blotting, and miR-100 by qPCR.
|
23778527 |
2013 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
|
17085196 |
2006 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping.
|
17803960 |
2007 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of FGFR3 are a common and early event in bladder cancer.
|
25223521 |
2015 |
|
Bladder Neoplasm
|
0.600 |
Biomarker
|
disease |
BEFREE |
Activating point mutations and protein overexpression of fibroblast growth factor receptors (FGFRs), especially FGFR3, are frequent events in bladder cancer.
|
24898159 |
2015 |
|
Bladder Neoplasm
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The detection of FGFR3 mutations in FUH further supports the role of this lesion as precursor of papillary bladder cancer.
|
16570285 |
2006 |